Showing 4001-4010 of 6035 results for "".
- iStar Medical Announces Positive 5-year Results of MINIject® in Glaucoma Patientshttps://modernod.com/news/istar-medical-announces-positive-5-year-results-of-miniject-in-glaucoma-patients/2482760/iStar Medical has announced positive 5-year results from the STAR-GLOBAL trial for their MINIject®device in patients with open-angle glaucoma. STAR-GLOBAL is an extension trial investigating the long-term safety and efficacy of MINIject® up to five years after im
- Nordic Pharma Launches Authorized Generic of Maxitrolhttps://modernod.com/news/nordic-pharma-launches-authorized-generic-of-maxitrol/2482759/Nordic Pharma announced a partnership with Harrow to launch an authorized generic of Maxitrol (Neomycin and Polymyxin B Sulfates and Dexamethasone ophthalmic suspension), for the treatment and relief of bacterial eye infections. Maxitrol and generic equivalents had a
- Focus Vitamins Launches New Daily Eye Health Supplement: Focus Luteinhttps://modernod.com/news/focus-vitamins-launches-new-daily-eye-health-supplement-focus-lutein/2482758/Focus Vitamins, a physician-founded nutraceutical company under Covalent Medical, has announced the launch of 'Focus Lutein,' a daily eye health supplement designed to support long-term vision and defend against age-related changes.
- Allotex Accelerates into Commercial Phase and Appoints Michael Mrochen as New CEOhttps://modernod.com/news/allotex-accelerates-into-commercial-phase-and-appoints-michael-mrochen-as-new-ceo/2482755/Allotex, which has developed the first natural, human collagen-based eye implant designed to help people over 40 restore their near vision, announced progress in its commercial rollout across global markets. Following market clearance in Europe, Canada, South Africa, Türkiye, and A
- CSI Dry Eye Software Announces Ken Barbet as New Chief Executive Officerhttps://modernod.com/news/csi-dry-eye-software-announces-ken-barbet-as-new-chief-executive-officer/2482754/Earlier this week, CSI Dry Eye Software, an artificial intelligence-based platform to aid dry eye disease management, announced Ken Barbet at the company’s new Chief Executive Officer (CEO). Mr. Barbet has 30 years of executive leade
- Johnson & Johnson to Present New Data for Tecnis Odyssey at ASCRShttps://modernod.com/news/johnson-johnson-to-present-new-data-for-tecnis-odyssey-at-ascrs/2482753/Johnson & Johnson will present data supporting the performance of the next-generation Tecnis Odyssey IOL at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Los Angeles. J&J is featuring 22 company sponsored and investigator led studies
- Brent Saunders: Bausch + Lomb to Return enVista IOLs to Market Following Voluntary Recallhttps://modernod.com/news/bausch-lomb-returning-envista-iols-to-market-following-voluntary-recall/2482752/Bausch + Lomb announced it has identified the event that led to its recent
- First Atropine Eye Drop to Slow Myopia Progression in Children Approved in Indiahttps://modernod.com/news/first-atropine-eye-drop-to-slow-myopia-progression-in-children-approved-in-india/2482750/Entod Pharmaceuticals announced it has received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for the first 0.05% atropine eye drops (Myatro XL) developed to slow the progression of myopia in children age 6 to 12. This milestone foll
- Sight Sciences Launches OMNI Edge Surgical System at ASCRShttps://modernod.com/news/sight-sciences-to-debut-omni-edge-surgical-system-at-ascrs/2482748/Sight Sciences announced the expansion of the OMNI product family by launching the OMNI Edge Surgical System. The new technology will debut at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, taking place April 25–27 in Los Angeles.<
- Neurotech Appoints Beth Marsh as Chief Commercial Officerhttps://modernod.com/news/neurotech-appoints-beth-marsh-as-chief-commercial-officer/2482746/Neurotech Pharmaceuticals announced the appointment of Beth Marsh as Chief Commercial Officer, effective April 28, 2025. In this role, Ms. Marsh will lead the commercial organization, including preparing for the US launch of Encelto (revakinagene taroretcel-lwey), the first and onl